Literature DB >> 22226112

Fibrotic and sclerotic manifestations of chronic graft-versus-host disease.

Carrie L Kitko1, Eric S White, Kristin Baird.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22226112      PMCID： PMC3260451          DOI： 10.1016/j.bbmt.2011.10.021

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN： 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  46 in total

1.  Development of a decellularized lung bioreactor system for bioengineering the lung: the matrix reloaded.

Authors:  Andrew P Price; Kristen A England; Amy M Matson; Bruce R Blazar; Angela Panoskaltsis-Mortari
Journal:  Tissue Eng Part A       Date:  2010-08       Impact factor: 3.845

2.  Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.

Authors:  Paul W Noble; Carlo Albera; Williamson Z Bradford; Ulrich Costabel; Marilyn K Glassberg; David Kardatzke; Talmadge E King; Lisa Lancaster; Steven A Sahn; Javier Szwarcberg; Dominique Valeyre; Roland M du Bois
Journal:  Lancet       Date:  2011-05-13       Impact factor: 79.321

3.  Bronchiolitis obliterans syndrome epidemiology after allogeneic hematopoietic cell transplantation.

Authors:  Brandon K C Au; Margaret A Au; Jason W Chien
Journal:  Biol Blood Marrow Transplant       Date:  2010-11-30       Impact factor: 5.742

4.  Rationale and design of the chronic GVHD cohort study: improving outcomes assessment in chronic GVHD.

Authors: 
Journal:  Biol Blood Marrow Transplant       Date:  2011-05-19       Impact factor: 5.742

5.  Patient-reported quality of life is associated with severity of chronic graft-versus-host disease as measured by NIH criteria: report on baseline data from the Chronic GVHD Consortium.

Authors:  Joseph Pidala; Brenda Kurland; Xiaoyu Chai; Navneet Majhail; Daniel J Weisdorf; Steven Pavletic; Corey Cutler; David Jacobsohn; Jeanne Palmer; Sally Arai; Madan Jagasia; Stephanie J Lee
Journal:  Blood       Date:  2011-02-25       Impact factor: 22.113

6.  The global severity of chronic graft-versus-host disease, determined by National Institutes of Health consensus criteria, is associated with overall survival and non-relapse mortality.

Authors:  Joseph Pidala; Jongphil Kim; Claudio Anasetti; Taiga Nishihori; Brian Betts; Teresa Field; Janelle Perkins
Journal:  Haematologica       Date:  2011-07-26       Impact factor: 9.941

7.  Critical role of tumor necrosis factor receptor 1, but not 2, in hepatic stellate cell proliferation, extracellular matrix remodeling, and liver fibrogenesis.

Authors:  Núria Tarrats; Anna Moles; Albert Morales; Carmen García-Ruiz; José C Fernández-Checa; Montserrat Marí
Journal:  Hepatology       Date:  2011-07       Impact factor: 17.425

8.  Sclerodermatous graft-vs-host disease: clinical and pathological study of 17 patients.

Authors:  Pablo F Peñas; María Jones-Caballero; Maximiliano Aragüés; Jesús Fernández-Herrera; Javier Fraga; Amaro García-Díez
Journal:  Arch Dermatol       Date:  2002-07

9.  Fluticasone, azithromycin and montelukast therapy in reducing corticosteroid exposure in bronchiolitis obliterans syndrome after allogeneic hematopoietic SCT: a case series of eight patients.

Authors:  B C Norman; D A Jacobsohn; K M Williams; B K C Au; M A Au; S J Lee; C K Moravec; J W Chien
Journal:  Bone Marrow Transplant       Date:  2010-12-06       Impact factor: 5.483

Review 10.  Diagnosis and treatment of pulmonary chronic GVHD: report from the consensus conference on clinical practice in chronic GVHD.

Authors:  G C Hildebrandt; T Fazekas; A Lawitschka; H Bertz; H Greinix; J Halter; S Z Pavletic; E Holler; D Wolff
Journal:  Bone Marrow Transplant       Date:  2011-03-28       Impact factor: 5.483
View more
  7 in total

Review 1.  NADPH oxidase enzymes in skin fibrosis: molecular targets and therapeutic agents.

Authors:  Olubukola Babalola; Andrew Mamalis; Hadar Lev-Tov; Jared Jagdeo
Journal:  Arch Dermatol Res       Date:  2013-10-24       Impact factor: 3.017

2.  Pirfenidone ameliorates murine chronic GVHD through inhibition of macrophage infiltration and TGF-β production.

Authors:  Jing Du; Katelyn Paz; Ryan Flynn; Ante Vulic; Tara M Robinson; Katie E Lineburg; Kylie A Alexander; Jingjing Meng; Sabita Roy; Angela Panoskaltsis-Mortari; Michael Loschi; Geoffrey R Hill; Jonathan S Serody; Ivan Maillard; David Miklos; John Koreth; Corey S Cutler; Joseph H Antin; Jerome Ritz; Kelli P MacDonald; Timothy W Schacker; Leo Luznik; Bruce R Blazar
Journal:  Blood       Date:  2017-03-02       Impact factor: 22.113

3.  Combined meta-analysis of systemic effects of allogeneic stem cell transplantation and systemic sclerosis.

Authors:  Dmitry N Grigoryev; Jignesh Dalal; Mara L Becker; Shui Q Ye
Journal:  BMC Hematol       Date:  2014-03-22

4.  Machine learning reveals chronic graft-versus-host disease phenotypes and stratifies survival after stem cell transplant for hematologic malignancies.

Authors:  Jocelyn S Gandelman; Michael T Byrne; Akshitkumar M Mistry; Hannah G Polikowsky; Kirsten E Diggins; Heidi Chen; Stephanie J Lee; Mukta Arora; Corey Cutler; Mary Flowers; Joseph Pidala; Jonathan M Irish; Madan H Jagasia
Journal:  Haematologica       Date:  2018-09-20       Impact factor: 9.941

Review 5.  Mast Cell Involvement in Fibrosis in Chronic Graft-Versus-Host Disease.

Authors:  Ethan Strattan; Gerhard Carl Hildebrandt
Journal:  Int J Mol Sci       Date:  2021-02-27       Impact factor: 5.923

6.  Targeting the Retinoid X Receptor Pathway Prevents and Ameliorates Murine Chronic Graft-Versus-Host Disease.

Authors:  Govindarajan Thangavelu; Michael C Zaiken; Fathima A Mohamed; Ryan Flynn; Jing Du; Stephanie Y Rhee; Megan J Riddle; Ethan G Aguilar; Angela Panoskaltsis-Mortari; Martin E Sanders; Bruce R Blazar
Journal:  Front Immunol       Date:  2022-03-11       Impact factor: 7.561

7.  Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar Study.

Authors:  Corey Cutler; Stephanie J Lee; Sally Arai; Marcello Rotta; Behyar Zoghi; Aleksandr Lazaryan; Aravind Ramakrishnan; Zachariah DeFilipp; Amandeep Salhotra; Wanxing Chai-Ho; Rohtesh Mehta; Trent Wang; Mukta Arora; Iskra Pusic; Ayman Saad; Nirav N Shah; Sunil Abhyankar; Carlos Bachier; John Galvin; Annie Im; Amelia Langston; Jane Liesveld; Mark Juckett; Aaron Logan; Levanto Schachter; Asif Alavi; Dianna Howard; Harlan W Waksal; John Ryan; David Eiznhamer; Sanjay K Aggarwal; Jonathan Ieyoub; Olivier Schueller; Laurie Green; Zhongming Yang; Heidi Krenz; Madan Jagasia; Bruce R Blazar; Steven Pavletic
Journal:  Blood       Date:  2021-12-02       Impact factor: 25.476
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.